Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Womens Health

Mark P. Thomas, Barry V.L. Potter

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and womens health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.

Original languageEnglish
Pages (from-to)7634-7658
Number of pages25
JournalJournal of Medicinal Chemistry
Volume58
Issue number19
Early online date12 Jun 2015
DOIs
Publication statusPublished - 8 Oct 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Womens Health. / Thomas, Mark P.; Potter, Barry V.L.

In: Journal of Medicinal Chemistry, Vol. 58, No. 19, 08.10.2015, p. 7634-7658.

Research output: Contribution to journalReview article

@article{7aabd0d712544d969d501c6495b196e8,
title = "Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Womens Health",
abstract = "In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and womens health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.",
author = "Thomas, {Mark P.} and Potter, {Barry V.L.}",
year = "2015",
month = "10",
day = "8",
doi = "10.1021/acs.jmedchem.5b00386",
language = "English",
volume = "58",
pages = "7634--7658",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Womens Health

AU - Thomas, Mark P.

AU - Potter, Barry V.L.

PY - 2015/10/8

Y1 - 2015/10/8

N2 - In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and womens health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.

AB - In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and womens health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future.

UR - http://www.scopus.com/inward/record.url?scp=84941247165&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b00386

DO - 10.1021/acs.jmedchem.5b00386

M3 - Review article

VL - 58

SP - 7634

EP - 7658

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -